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 2 
Abstract  39 
 40 
Background – Antimicrobial resistance has become a major challenge in veterinary 41 
medicine, particularly in the context of bacterial pathogens that play a role in humans 42 
and animals. 43 
 44 
Objectives – This review serves as an update on acquired resistance mechanisms 45 
in bacterial pathogens of human and animal origin, including examples of transfer of 46 
resistant pathogens between hosts and of resistance genes between bacteria. 47 
 48 
Results – Acquired resistance is based on resistance-mediating mutations or on 49 
mobile resistance genes. While mutations are transferred vertically, mobile resistance 50 
genes are transferred also horizontally (by transformation, transduction or 51 
conjugation/mobilization), contributing to the dissemination of resistance. Mobile 52 
genes specifying any of the three major resistance mechanisms – enzymatic 53 
inactivation, reduced intracellular accumulation or modification of the cellular target 54 
sites – have been found in a variety of bacteria from animals. Such resistance genes 55 
are associated with plasmids, transposons, gene cassettes, integrative and 56 
conjugative elements or other mobile elements. Bacteria, including zoonotic 57 
pathogens, can be exchanged between animals and humans mainly via direct 58 
contact, but also via dust and aerosols or via the food chain. Proof of the direction of 59 
transfer of resistant bacteria can be difficult and depends on the location of 60 
resistance genes or mutation in the chromosomal DNA or on a mobile element. 61 
 62 
Conclusion – The wide variety in resistance and resistance transfer mechanisms will 63 
continue to ensure the success of bacterial pathogens in the future. Our strategies to 64 
counteract resistance and preserve efficacy of antimicrobial agents needs to be equally 65 
diverse and resourceful.  66 
67 
 3 
Introduction 68 
 69 
Antimicrobial agents are used extensively in aquaculture, horticulture, and to treat 70 
bacterial infections in humans and animals. Due to this extensive use, antimicrobial 71 
resistance has become a significant problem in both human and veterinary medicine, 72 
mediated by a multitude of mechanisms.1, 2 Although the presence of resistance 73 
genes in bacteria is not a new phenomenon – as recently highlighted in a study 74 
describing resistance genes in bacterial DNA from permafrost soil samples3 – what is 75 
new is the selective pressure exerted on bacterial pathogens through antibacterial 76 
use. Since the 1950s, the selective pressure imposed on bacteria by the use of 77 
antimicrobial agents for various clinical and nonclinical purposes has increased 78 
dramatically. As a consequence, bacteria have developed and refined various ways 79 
and means to resist or escape the inhibitory effects of the antimicrobial agents.1, 2 In 80 
addition, certain bacterial pathogens have managed to accumulate or develop 81 
resistances to multiple classes of antimicrobial agents at the same time. Such 82 
multidrug-resistant, extensively resistant or even pan-drug resistant pathogens4 83 
typically succeed in human and veterinary healthcare establishments or in patients 84 
repeatedly requiring antibacterial therapy. Risk groups include dogs with recurrent 85 
pyoderma. Such patterns of resistance may seriously compromise the prognosis of 86 
infected patients. As a result, for the first time in decades, the prognosis for patients 87 
with infections caused by multidrug-resistant bacteria has been seriously 88 
compromised by the lack of effective antimicrobial agents. This development has 89 
threatened the advancement of modern medicine.5 90 
 91 
Antimicrobial resistance 92 
 93 
A bacterium is defined as being clinically resistant to an antimicrobial agent when the 94 
drug – after recommended dosing – does not reach a concentration at the site of 95 
infection that is able to effectively inhibit the growth of the bacterium or to kill it.6 This 96 
definition takes into account the pharmacological parameters relevant for systemic 97 
therapy of the antimicrobial agent in the patient species concerned. It also considers 98 
the minimum inhibitory concentration (MIC) of the causative bacteria to the 99 
antimicrobial agent applied. These factors, along with the results of clinical efficacy 100 
studies, play key roles in the definition of clinical breakpoints.6 Such clinical 101 
breakpoints are available for humans and various animal species as recommended 102 
by the Clinical and Laboratory Standards Institute (CLSI) and usually are applicable 103 
for a specific combination of host species/target bacterium/antimicrobial 104 
agent/disease condition, such as dog/Staphylococcus spp./tetracycline/skin and soft 105 
tissue infections.7, 8 In general, these breakpoints were derived from microbiological, 106 
pharmacokinetic (using accepted clinical doses) and pharmacodynamic data. In the 107 
veterinary field, clinical breakpoints applicable for bacteria involved in skin and soft 108 
tissue infections are available for the canine, feline and equine bacteria shown in 109 
Table 1. 110 
 111 
In general, antimicrobial resistance in bacteria can be either intrinsic or acquired. 112 
Intrinsic resistance is a bacterial genus- or species-specific characteristic and is often 113 
based on either the absence or inaccessibility of the target structures in the 114 
respective bacteria,1 for example, resistance to β-lactam antibiotics and 115 
glycopeptides in cell wall-free bacteria such as Mycoplasma spp. or vancomycin 116 
resistance in Gram-negative bacteria due to the inability of vancomycin to penetrate 117 
the outer membrane. It can also be due to the presence of export systems or the 118 
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production of species-specific inactivating enzymes in certain bacteria,1 such as the 119 
AcrAB-TolC system and the production of AmpC β-lactamase in Escherichia coli. In 120 
addition, some bacteria, such as enterococci, are not dependent on a functional 121 
folate synthesis pathway, but instead can use exogenous folates. As a consequence, 122 
they are intrinsically resistant to folate pathway inhibitors, such as trimethoprim and 123 
sulfonamides.9 In contrast, acquired resistance is a strain-specific property which can 124 
be based on a wide variety of resistance mechanisms present in the different 125 
bacteria.1 Such acquired resistance mechanisms can be due to mutations of cellular 126 
genes or to the acquisition of novel/foreign genes, commonly referred to as 127 
resistance genes. The following basic considerations are important in the context of 128 
acquired resistance genes: 129 
 130 
1. Acquired resistance genes can confer resistance to an entire class of 131 
antimicrobial agents or can be specific for only a single member of an 132 
antimicrobial class. 133 
2. Certain acquired resistance genes can confer resistance to members of 134 
different classes of antimicrobial agents.  135 
3. Acquired resistance to a specific class of antimicrobial agents can be due to 136 
several different resistance mechanisms.  137 
4. The same acquired resistance mechanism can be encoded by different genes. 138 
5. Different acquired resistance mechanisms and resistance genes can be 139 
present at the same time.  140 
6. Definitions of multidrug-resistance vary but a bacterium is typically referred to 141 
as multidrug-resistant if it shows acquired resistance to members of at least 142 
three classes of antimicrobial agents. 143 
 144 
Resistance mechanisms and associated resistance genes 145 
 146 
Acquired resistance mechanisms can be divided into one of the three major 147 
categories: (i) enzymatic modification or inactivation of antimicrobial agents, (ii) 148 
reduced intracellular accumulation of antimicrobial agents or (iii) alterations at the 149 
target sites of the antimicrobial agents.1, 2 150 
 151 
Enzymatic inactivation of antimicrobial agents is widespread among Gram-152 
positive and Gram-negative bacteria (Table 2). In the case of enzymatic modification, 153 
bacteria produce enzymes that chemically modify the drug molecule by the 154 
attachment of acetyl, adenyl or phosphate groups to specific sites of the antimicrobial 155 
molecule. Such modified antimicrobial molecules can no longer bind to their target 156 
site and consequently cannot maintain antimicrobial activity. This mechanism is 157 
commonly used for the enzymatic inactivation of nonfluorinated phenicols, such as 158 
chloramphenicol, by acetylation,10 or of aminoglycosides by acetylation, adenylation 159 
or phosphorylation.11 Other enzymatic inactivation processes include the 160 
phosphorylation of macrolides, nucleotidylation of lincosamides, and acetylation of 161 
streptogramin A antibiotics. 162 
 In the case of enzymatic inactivation, bacteria produce enzymes that bind 163 
directly to the antimicrobial molecule and disintegrate it. This is commonly done by 164 
hydrolytic cleavage of specific bonds within the antimicrobial molecule. Such cleaved 165 
antimicrobial molecules also do not exhibit antimicrobial activity. Examples of this 166 
mode of enzymatic inactivation are the β-lactamases, which occur in Gram-positive 167 
and Gram-negative bacteria and, depending on the type of β-lactamase, may exhibit 168 
a more or less expanded substrate spectrum that can include penicillins, 169 
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cephalosporins, monobactams and/or even carbapenems.12, 13 Other examples are 170 
esterases which confer macrolide resistance or lactone hydrolases which inactivate 171 
streptogramin B compounds.14 172 
 173 
Reduced intracellular accumulation of antimicrobial agents can be achieved 174 
in two ways: reduced influx or enhanced efflux (Table 3). It is known that certain 175 
outer membrane proteins (OMPs), so-called porins, represent an entry point for 176 
antimicrobial agents to enter the bacterial cell. As such, OmpF is involved in the 177 
uptake of tetracyclines, β-lactams and chloramphenicol in E. coli, whereas OmpD is 178 
involved in the uptake of carbapenems in Pseudomonas aeruginosa.1 Reduced influx 179 
of antimicrobial agents is usually the consequence of downregulation, structural 180 
modification or even functional deletion of the genes coding for these porins. In such 181 
cases, the outer membrane of Gram-negative bacteria can represent a permeability 182 
barrier for antimicrobial agents. 183 
By contrast, increased efflux describes a way by which incoming antimicrobial 184 
agents are actively pumped out of the bacterial cell. This can be achieved by 185 
multidrug transporters or specific transporters.1, 2 Multidrug transporters are present 186 
in virtually every bacterium and are mainly responsible for the transport of toxic 187 
substances from the cell metabolism. However, studies have shown that some 188 
multidrug transporters can also export antimicrobial agents. Most of them belong to 189 
the resistance-nodulation-cell division (RND) family. RND transporters mainly occur 190 
in Gram-negative bacteria and are composed of a cytoplasmatic and a periplasmatic 191 
component which can interact with different outer membrane components. Examples 192 
are AcrAB-TolC transporter in E. coli and Salmonella enterica or the MexAB-OprM 193 
transporter in P. aeruginosa which can export chloramphenicol, fluoroquinolones, 194 
tetracyclines, β-lactams and macrolides among others.1, 15 It should be noted that 195 
multidrug-transporters increase the MICs for their substrates, but not necessarily to a 196 
level that correlates with clinical resistance. 197 
Specific transporters involved in antimicrobial resistance commonly belong to 198 
the following families: (i) major facilitator superfamily (MFS), (ii) ATP-binding cassette 199 
(ABC) family or (iii) multidrug and toxic-compound extrusion (MATE) family.15, 16 MFS 200 
transporters often consist of 12–14 transmembrane segments, exchange a drug 201 
molecule against a proton and use the proton-motive force of the membrane as an 202 
energy source for the translocation. Examples of MFS transporters are the 203 
tetracycline transporters Tet(K) and Tet(L) in Gram-positive bacteria and Tet (A-E, G, 204 
H) in Gram-negative bacteria as well as the phenicol transporters FexA in Gram-205 
positive bacteria and FloR, CmlA and CmlB in Gram-negative bacteria.17, 18 ABC 206 
transporters use the energy of ATP hydrolysis for the translocation of substrates 207 
across biological membranes. They represent a highly diverse class of transporters 208 
which are not only involved in antimicrobial resistance, but also in the uptake of 209 
nutrients and the secretion of proteins among other functions.19 ABC transporters 210 
involved in antimicrobial resistance are seen mainly in staphylococci and enterococci. 211 
Examples are the transporters Vga(A), Vga(C), Vga(E), Lsa(E) and Sal(A) conferring 212 
combined resistance to lincosamides, pleuromutilins and streptogramin A antibiotics 213 
or Msr(A) involved in resistance to macrolides and streptogramin B antibiotics.20, 21 214 
MATE proteins are also located in the cytoplasmatic membrane and act in a similar 215 
way to MFS transporters. However, in contrast to MFS proteins, they are rarely 216 
involved in antimicrobial resistance. Examples of MATE proteins that export 217 
antimicrobial agents are NorM (hydrophilic fluoroquinolones) from Vibrio 218 
parahaemolyticus and MepA (glycylcyclines) from Staphylococcus aureus.15, 16 219 
 220 
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Alterations at the target sites of the antimicrobial agents represent the third 221 
and most variable group of resistance mechanisms (Table 4). These include 222 
mutational and chemical modifications, protection of the target sites, the replacement 223 
of sensitive targets by functionally analogous but insensitive ones, and 224 
overproduction of sensitive targets.22 225 
Mutational alterations of the target sites are best known for (fluoro)quinolone 226 
resistance in various Gram-positive and Gram-negative bacteria. Within the genes for 227 
DNA gyrase (topoisomerase II and topoisomerase IV), a specific region known as the 228 
quinolone-resistance determining region (QRDR) has been defined where mutations 229 
accounting for (fluoro)quinolone resistance are located. Resistance to 230 
(fluoro)quinolones usually occurs in a step-wise manner by which the MIC is 231 
increased with each additional mutation.23, 24 Such a step-wise increase in resistance 232 
illustrates well the advantage of using mutant prevention concentrations (MPCs) as a 233 
measure for antimicrobial potency rather than MICs.25 Because two mutations are 234 
required for full (fluoro)quinolone resistance to occur, and with mutations occurring 235 
randomly, the likelihood that bacteria with double mutations will persist after 236 
treatment is low and measurable only in a large population of cells (i.e. in large 237 
numbers of colony forming units in the laboratory). To date, MPC measurement has 238 
not been applied routinely in clinical microbiology laboratories, possibly hampered by 239 
practical constraints.26 240 
Mutations in the gene fusA, which encodes the elongation factor G (EF-G), 241 
have been found to account for resistance to fusidic acid in S. aureus as well as in 242 
meticillin-susceptible (MSSP) and meticillin-resistant Staphylococcus 243 
pseudintermedius (MRSP).27, 28 Mutations in 16S ribosomal RNA (rRNA) have been 244 
described to account for resistance to streptomycin in Mycobacterium tuberculosis, to 245 
tetracyclines in Propionibacterium acnes and to spectinomycin resistance in 246 
Pasteurella multocida.1, 29 Mutations in 23S rRNA are known to cause macrolide 247 
resistance in various bacteria including Mycobacterium spp., Brachyspira 248 
hyodysenteriae, Campylobacter coli, Campylobacter jejuni, Haemophilus influenzae 249 
and Streptococcus spp. among others.1 In addition, mutations in the genes for 250 
specific ribosomal proteins are associated with resistance to streptomycin and 251 
spectinomycin.1, 29 Mutations in the gene rpoB, which codes for the β-subunit of the 252 
enzyme RNA polymerase, have been described recently to cause high-level 253 
rifampicin resistance in Rhodococcus equi and in MRSP.30, 31 254 
Chemical modification of the target site by methylation has proved to be an 255 
effective way to confer combined resistance to macrolides, lincosamides and 256 
streptogramin B antimicrobial agents. The corresponding Erm methylases, which 257 
target the adenine residue at position 2058 in 23S rRNA, are widely distributed 258 
among Gram-positive and Gram-negative bacteria.32 To date, 46 different Erm 259 
methylases have been differentiated.33 Methylation of the adenine residue at position 260 
2503, which is located in the overlapping binding region of phenicols, lincosamides, 261 
oxazolidinones, pleuromutilins and streptogramin A antibiotics, results in resistance 262 
to these five classes of antimicrobial agents.34 The corresponding methylase gene, 263 
cfr, has been detected in various Staphylococcus spp., Enterococcus spp., Bacillus 264 
spp., Macrococcus caseolyticus, Jeotgalicoccus pinnepedialis, Streptococcus suis, E. 265 
coli and Proteus vulgaris.20, 35 Recently, the gene cfrB, which confers the same 266 
resistance phenotype but is <80% identical to cfr, has been detected in Enterococcus 267 
spp. and Clostridium difficile isolates.17, 33 268 
Protection of the ribosomal target site has been noted in tetracycline resistance. 269 
So far, 12 ribosome protective proteins are known which show similarities to 270 
elongation factor EF-G. These proteins bind to the ribosome, do not interfere with 271 
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protein synthesis, but protect the ribosome from the inhibitory effects of 272 
tetracyclines.36, 37 The gene fusB also codes for an EF-G-binding protein that protects 273 
the staphylococcal ribosomes from inhibition by fusidic acid.27 274 
The replacement of a sensitive target by an alternative drug-resistant target is 275 
well known in sulfonamide and trimethoprim resistance. The sulfonamide resistance 276 
genes sul1, sul2 or sul3, which code for sulfonamide-insensitive dihydropteroate 277 
synthases, are widespread in Gram-negative bacteria.1, 2 Gram-negative and Gram-278 
positive bacteria have acquired various dfr genes which code for trimethoprim-279 
insensitive dihydrofolate reductases.1, 2 In addition, the genes mecA and mecC, 280 
present in various Staphylococcus spp., code for alternative penicillin-binding 281 
proteins which exhibit a substantially reduced affinity to virtually all β-lactam 282 
antimicrobial agents. Moreover, the genes vanA–vanE code for alternative D-Ala–D-283 
Lac or D-Ala–D-Ser peptidoglycan precursors that render the respective bacteria 284 
resistant to glycopeptides, which also act at the level of cell wall synthesis.1, 2, 38 285 
Sulfonamide resistance via the hyper-production of p-aminobenzoic acid has 286 
been observed in isolates of the genera Staphylococcus and Neisseria. Likewise, 287 
promoter mutations resulting in the overproduction of a trimethoprim-susceptible 288 
dihydrofolate reductase have been described to account for trimethoprim resistance 289 
in E. coli and Haemophilus influenzae.22 290 
Additional discussions of MIC distributions, as well as resistance genes and the 291 
mechanisms specified by them in bacteria involved in skin and soft tissue infections 292 
of animals, including staphylococci, streptococci and Gram negative bacteria, are 293 
available in other articles and book chapters.39-54 294 
 295 
Horizontal gene transfer and mobile genetic elements involved 296 
 297 
 As resistance-mediating mutations usually are located in essential 298 
chromosomal genes or in the 16S and 23S rRNA, they can only be transferred 299 
vertically during cell division.1, 2 It is important that such mutations should not 300 
negatively affect the fitness of the bacteria. In contrast, mobile resistance genes are 301 
transferred vertically and horizontally, and thereby contribute to the dissemination of 302 
resistance properties.1, 2, 55 Horizontal gene transfer (HGT) from the donor cell occurs 303 
via transformation, transduction or conjugation/mobilization and may include recipient 304 
cells of the same species, the same genus but also of different species and genera. 305 
 306 
Transformation describes the transfer of “naked” DNA. It is the usual way used to 307 
transfer DNA under in vitro conditions. Although it also occurs in nature, it is believed 308 
to play a minor role in the transfer of DNA under natural conditions.1, 2, 55 309 
 310 
Transduction describes the transfer of DNA via bacteriophages. Limitations to 311 
transduction are (i) the size of the head of the transducing phages into which 312 
plasmids or other DNA elements are packaged and (ii) the requirement for receptors 313 
on the recipient cell to which the transducing phage can attach. Thus, only a limited 314 
amount of DNA, approximately 45 kb for staphylococci, can be transduced and 315 
transduction occurs mainly between members of the same or closely related bacterial 316 
species.1, 2, 55 317 
 318 
Conjugation, however, can also occur between bacteria of different species and 319 
genera. It describes the self-transfer of a conjugative element from a donor to a 320 
recipient cell. Plasmids and transposons can be conjugative, whereas integrative and 321 
conjugative elements (ICEs) are by definition always conjugative. The conjugative 322 
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element harbours a tra gene complex which specifies the transfer apparatus. If a 323 
conjugative element provides its transfer apparatus to nonconjugative elements, 324 
mainly plasmids that co-reside in the same donor cell, such nonconjugative plasmids 325 
can move over to the recipient cell. This process is referred to as mobilization. 326 
Conjugation and mobilization of various mobile genetic elements are believed to play 327 
key roles in the dissemination of antimicrobial resistance in bacteria.1, 2, 55 328 
Furthermore, dissemination is thought to be particularly efficient amongst bacteria of 329 
the same species or clonal lineage. Barriers to HGT gene transfer, which protect 330 
bacteria against “foreign” DNA from other bacterial species or lineages, have been 331 
identified and are now widely described in many bacterial species.56 Barrier systems 332 
described in staphylococci, including S. pseudintermedius, include restriction-333 
modification systems, competence genes and Clustered Regularly Interspaced Short 334 
Palindromic Repeats (CRISPR) systems, and these have been linked to the 335 
successful spread of certain lineages and their ability to protect themselves from 336 
foreign DNA.57 However, their role in preventing acquisition of resistance genes, at 337 
least in S. pseudintermedius, is questionable based on finding them distributed 338 
randomly amongst multidrug-resistant and -susceptible isolates.28 339 
 340 
There are several mobile genetic elements (MGEs) which can harbour antimicrobial 341 
resistance genes and which are essential to horizontal gene transfer. All of them are 342 
double-stranded DNA molecules. Plasmids are the most abundant MGEs. They can 343 
vary distinctly in their sizes between < 2 kb and > 200 kb. Plasmids replicate 344 
autonomously and independently from the chromosomal DNA. They can carry 345 
antimicrobial resistance genes, heavy metal resistance genes, virulence genes and 346 
genes for a number of other properties, including metabolic functions. Plasmids can 347 
harbour transposons and gene cassettes/integrons. 348 
 349 
Transposons differ distinctly in size and structure. In contrast to plasmids, they are 350 
replication-deficient and as such must integrate for their replication either into 351 
plasmids or the chromosomal DNA. They move by transposition, either into specific 352 
sites or into various sites in plasmids or in the chromosomal DNA. The importance of 353 
large transposons in the emergence of the extremely drug resistant phenotypes was 354 
recently highlighted by the identification of a Tn5405-like element carrying up to five 355 
antimicrobial resistance genes in all of 11 fully sequenced multidrug-resistant MRSP 356 
isolates of four different lineages.28 357 
 358 
Gene cassettes are the smallest MGEs which commonly carry only one gene, mostly 359 
an antimicrobial resistance gene, and a recombination site, known as the 59-base 360 
element. They can neither replicate nor transpose. They move by site-specific 361 
recombination and are commonly found in integrons. The integrase of the integron 362 
catalyses the integration and excision of the gene cassette using the 59-base 363 
element. As gene cassettes usually do not have an own promoter, the cassette-364 
borne gene is transcribed from a promoter in the 5′-conserved region of the integron. 365 
Gene cassettes are rarely found at secondary sites outside of an integron.1, 2, 55 366 
 367 
Integrative and conjugative elements (ICEs) are large elements of >20 kb which 368 
integrate site-specifically into the chromosomal DNA. They can excise from the 369 
chromosomal DNA, form a circular intermediate and transfer themselves via a 370 
replicative cycle into new host cells where they integrate again into the chromosomal 371 
DNA. In terms of antimicrobial multidrug-resistance, the SXT element of Vibrio 372 
cholerae and the ICEPmu1 from P. multocida are well-studied ICEs.58-60 The latter 373 
 9 
has been shown to carry and transfer a total of 12 different antimicrobial resistance 374 
genes conferring resistance to eight classes of antimicrobial agents.59, 60 Other 375 
elements that integrate site-specifically into the chromosomal DNA of the respective 376 
bacteria include the various different types of the SCCmec elements in staphylococci, 377 
as well as the numerous variants of the integrative and mobilizable Salmonella 378 
genomic islands SGI1, SGI2 and PGI1 in S. enterica and Proteus mirabilis.1, 2, 38, 61-63 379 
Why the composition and predominant types of MGEs vary between species (e.g. 380 
plasmids predominate in S. aureus whereas transposons are more frequently 381 
described in S. pseudintermedius), remains to be answered.28, 40, 57 382 
 383 
Consequences of the use of antimicrobial agents 384 
 385 
Whenever antimicrobial agents are applied to either humans or animals, a selective 386 
pressure is set under which susceptible bacteria are inhibited in their growth or killed, 387 
whereas resistant bacteria can propagate at the expense of the susceptible 388 
bacteria.64, 65 Antimicrobial agents do not differentiate between beneficial and 389 
pathogenic bacteria. They inhibit or kill all those bacteria for which MICs are at or 390 
below the antimicrobial concentration in the respective body compartment. As a 391 
consequence, the proportion of resistant bacteria increases during antimicrobial 392 
therapy and the composition of the microbiota is altered. This is true for virtually 393 
every antimicrobial agent and every human or animal host. Under the selective 394 
pressure imposed by the use of antimicrobial agents, antimicrobial resistance genes 395 
can also be disseminated between different bacteria within the same host.1, 64, 65 396 
However, when resistant bacteria are transferred between humans or between 397 
animals, they can also exchange their resistance genes with bacteria already 398 
resident in or on the new host.64, 65 399 
 400 
There are three basic requirements that favour the exchange of resistance genes: (i) 401 
close spatial contact between the exchange partners (which is present in the 402 
polymicrobial environments of the respiratory and intestinal tracts and also on the 403 
skin); (ii) location of the resistance genes on MGEs (which is given by the fact that 404 
most resistance genes are located on plasmids, transposons, gene cassettes and 405 
ICEs) and (iii) a selective pressure (which is provided by the application of 406 
antimicrobial agents).55 Exchange via horizontal gene transfer may involve obligatory 407 
and facultatively pathogenic bacteria as well as the commensal microbiota. If a 408 
multidrug-resistance MGE is transferred to new bacterial host and this host cell gains 409 
all the resistance genes associated with the MGE, the selective pressure imposed by 410 
the use of a single antimicrobial agent will ensure that the new host cell does not lose 411 
the multidrug-resistance MGE.64, 65 This means that the co-location of resistance 412 
genes furthers their co-selection and persistence even if no direct selective pressure 413 
is present. Thus, measures such as the voluntary withdrawal or even the ban of the 414 
use of an antimicrobial agent will not necessarily lead to a decrease in resistance. To 415 
better understand processes such as co-selection and persistence, and to judge the 416 
efficacy of the aforementioned measures, in-depth knowledge of the genetics of 417 
antimicrobial resistance is indispensable. 418 
 419 
Exchange of resistant bacteria between animals and humans  420 
 421 
As shown in Figure 1, the application of antimicrobial agents in human medicine 422 
as well as in veterinary medicine and food animal production can lead to the 423 
evolution and dissemination of resistant bacteria among humans and animals, 424 
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respectively.65 Depending on the virulence of the resistant bacteria, they may cause 425 
clinical diseases with limited treatment options. Transfer of bacteria – including 426 
resistant strains – can be exchanged between humans and animals in both directions 427 
by either contact, inhalation of dust and aerosols that contain bacteria, or via the food 428 
chain.65 429 
Direct contact is likely the quickest and easiest way by which bacteria are 430 
transferred in either direction between humans and animals, particularly for those 431 
such as staphylococci which reside on body surfaces. Anyone who shares close 432 
contact with pets or companion animals may be affected.66 In this regard, it is 433 
important to consider the current role of dogs and cats as actual family members in 434 
many households in industrialized countries. A study published in 2014 revealed the 435 
presence of approximately 11.5 million cats, 6.9 million dogs, 6.1 million other pet 436 
animals (e.g. rabbits, guinea pigs, hamsters) and 3.4 million pet birds in German 437 
households.67 Pet owners often have extensive contact with their pets, especially to 438 
cats and dogs which may be allowed lick their owners’ faces and hands or to sleep in 439 
their owners’ beds.67, 68 Based on this close contact, a transfer of bacteria between 440 
pets and people is unavoidable and not surprising.66, 69-72 As “family members”, cats, 441 
dogs and other pet animals often enjoy not only an extensive support in terms of food 442 
supply and housing, but also broad medical care. In Germany, pet owners spent 443 
almost €4.8 billion for pet supplies in 2013, of which €3.75 billion accounted for pet 444 
food and €1.05 billion for equipment.67 For medical care of their pets, Germans spent 445 
approximately €2.1 billion in 2013.67 These data clearly show that pet owners have 446 
considerable interest in maintaining the health of their pets. As many infectious 447 
diseases in cats and dogs are caused by bacteria, particularly those infecting the skin 448 
of dogs,73 this also involves the application of antimicrobial agents. A wide range of 449 
antimicrobial agents has been licensed for use in cats and dogs. In addition, 450 
antimicrobial agents approved for use in human medicine may also be applied to 451 
nonfood-producing animals under the Animal Medicinal Drug Use Clarification Act 452 
(AMDUCA) in the USA or similar regulations in other countries.74 Although such 453 
applications should be kept to a minimum, it means that antimicrobial agents of last 454 
resort in human medicine, such as carbapenems, glycopeptides, oxazolidinones or 455 
lipopeptides, may be used in small animal medicine. However, no data are available 456 
to allow quantification of the use of these last resort agents for cats and dogs. 457 
 458 
Animal transmission to companion animal owners  459 
There have been numerous examples of the transfer of resistant bacteria, 460 
especially staphylococci and E. coli, between pets and people, beginning with the 461 
landmark report of the possible zoonotic spread of MRSA by a cat to hospitalized 462 
people.75 Reports of interspecies transmission of MRSA include: livestock-associated 463 
(LA-) MRSA ST398-t034 transferred from a colonized veterinarian to his dog,70 464 
healthcare-associated MRSA ST225-t014 transferred from a family member (who 465 
suffered from an infected decubitus ulcer) to the family dog,70 MRSA ST80-t131 466 
isolated from a woman who suffered from multiple recurrent skin abscesses and her 467 
husband, children and a cat living in the same household (where the patient's 468 
disease resolved completely after topical decolonization of all family members 469 
including the MRSA-positive cat),76 and the likely horse-to-human transmission of a 470 
LA-MRSA ST398-t011.77 MRSA colonization of persons in contact with infected or 471 
colonized horses has been reported from the investigation of several outbreaks.78 472 
Aside from MRSA, indistinguishable isolates of S. pseudintermedius ST33 have been 473 
reported from a dog and its owner.69 474 
 475 
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Typically, such reports are based on evidence from genetic typing studies which 476 
identify indistinguishable isolates from animals and in-contact humans. However, the 477 
direction of inter-host transmission can rarely be proven definitively, but rather, is 478 
often deduced from epidemiological characteristics. Even an MRSA outbreak 479 
investigation in a small animal hospital using whole genome sequencing of multiple 480 
isolates from each sample had to conclude that directions of transmission could only 481 
be suspected.79 For MRSA isolated from dogs and cats, for example, a 482 
predominantly human-to-animal direction of transmission is assumed because most 483 
isolates belong to MRSA clonal lineages that are also prevalent in human healthcare 484 
facilities and thus likely represent a “spill-over” to pets.69, 70, 80, 81 485 
 486 
Evidence for transmission of Gram-negative pathogens between animals and 487 
humans is only just beginning to emerge, but already includes some highly drug-488 
resistant nosocomial pathogens, such as E. coli ST410 and other multidrug-resistant 489 
Extended Spectrum Beta Lactamase-producing (ESBL) E. coli.82-84 Escherichia coli 490 
isolates, which belonged to the same phylogenetic group (B2 or D) and exhibited the 491 
same Amplified Fragment Length Polymorphism patterns, were detected among 492 
family members and their dogs.68 493 
 494 
People with occupational contact to animals 495 
In addition to pet and companion animal owners, people who have occupational 496 
contact with animals also are at risk for acquisition of bacteria from animals. Notably, 497 
these include veterinarians, but also veterinary students, farmers, abattoir workers 498 
and other animal caretakers. These people often work in an environment where they 499 
care for sick animals and in which antimicrobial agents are applied. Besides direct 500 
contact with animals, dust and aerosols, especially on farms and in abattoirs, may 501 
also play a role as vehicles that transport resistant bacteria and are inhaled by 502 
animals and humans. 503 
 504 
There are a number of published reports which suggest occupational 505 
transmission in various settings. In a small animal clinic, multidrug-resistant 506 
Staphylococcus epidermidis ST5 was shown to be present at various locations in the 507 
stationary area and the quarantine ward, as well as in feline patients and in the nose 508 
of one veterinary nurse.85 A study from Australia revealed that veterinarians often 509 
carry multidrug-resistant MRSA isolates.86 A study conducted in Germany showed 510 
that 97 (85.8%) of 113 swine farmers but only five (4.3%) of their 116 family 511 
members were positive for LA-MRSA.87 Likewise, 22 (44.9%) of 49 swine 512 
veterinarians but only four (9.1%) of their 44 family members were positive for LA-513 
MRSA in another report.87 These observations suggest that the human-to-human 514 
transfer of LA-MRSA occurs distinctly more rarely than the animal-to-human transfer. 515 
A study involving 26 dairy farms in the Netherlands revealed that the same LA-MRSA 516 
types, based on pulsed-field gel electrophoresis (PFGE) type, spa type and 517 
resistance patterns, were detected not only among dairy cattle and their contact 518 
personnel (e.g. milkers), but occasionally also among other animals living on the 519 
same farm.88 520 
 521 
LA-MRSA isolates with the molecular characteristics ST398-t011-dt11a and 522 
ST9-t1430-dt10a, both with very similar PFGE patterns and resistance phenotypes, 523 
were detected among poultry and workers in a Dutch poultry abattoir.89 The analysis 524 
of turkey flocks and their carers revealed that almost 60% of the farm personnel were 525 
colonized by LA-MRSA that exhibited the same spa type and SCCmec type as the 526 
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turkeys.90 A study on the transmission of LA-MRSA on broiler farms in the 527 
Netherlands revealed the presence of MRSA ST398-t034-dt10q with 528 
indistinguishable PFGE and resistance patterns among the broilers, dust samples 529 
from the broiler house and the farmer.91 The emission of bacteria from pig fattening 530 
and broiler chicken farms to the surrounding area was confirmed by the detection of 531 
ESBL-/AmpC-producing E. coli in air samples from inside as well as outside the farm 532 
buildings.92, 93 Another study showed that food animal transport in open crates 533 
resulted in the dissemination of bacteria, including resistant enterococci, into the 534 
environment.94 In addition, indirect transmission via insects or rats can occur on 535 
farms.95, 96 536 
 537 
Transmission via the food chain  538 
 539 
Transfer of resistant bacteria via the food chain usually occurs by ingestion of 540 
raw or insufficiently heated, contaminated food. In this regard, it is worth noting that 541 
(i) the number of ingested bacteria must be sufficiently high to survive the passage 542 
through the acidic environment in the stomach, which varies according to the type of 543 
foodborne pathogen and (ii) the virulence of most food-borne pathogens is more 544 
relevant than their antimicrobial resistance due to the fact that antimicrobial agents 545 
are not recommended for use in uncomplicated self-limiting cases of intestinal 546 
infections.97 However, when resistant bacteria are ingested, they may transfer 547 
antimicrobial resistance genes to members of the intestinal microbiota of the host. 548 
Unfortunately, there are little if no data which provide reliable information about the 549 
extent at which bacteria transfer their resistance genes during transient colonization 550 
of a new host.  551 
 552 
Proof of transfer of resistant bacteria and resistance genes 553 
 554 
In view of the many opportunities for exchange of resistant bacteria and resistance 555 
genes amongst human and animal hosts and the respective selection pressures, a 556 
key question is: what proportion of resistance problems in human medicine is caused 557 
by bacteria of animal origin? One study has assessed the impact of antimicrobial 558 
resistance in different bacterial species and of the contribution of animal sources to 559 
resistance in human infections.98 Based on the results of a questionnaire sent to 560 
recognized experts in the UK and elsewhere, the authors concluded that bacteria 561 
from animal sources, mainly nontyphoid Salmonella enterica serovars, E. coli O157, 562 
Campylobacter spp. and vancomycin-resistant enterococci, might account for 3.88% 563 
of the human antibiotic resistance problem.98 It should be noted that this survey was 564 
conducted at a time when LA-MRSA and ESBL-producing E. coli were not yet 565 
recognized as emerging zoonotic problems.99 Nevertheless, this survey suggested 566 
strongly that most of the resistance problems encountered in human medicine as well 567 
as in veterinary medicine are self-made problems in either sector. Only a minority 568 
results from the transfer of zoonotic bacteria. 569 
 570 
A study on zoonotic MRSA colonization and infection in Germany showed that 571 
zoonotic transmission of LA-MRSA CC398 from livestock to humans occurs 572 
predominantly in people with occupational livestock contact, whereas dissemination 573 
in the general population is limited so far.100 LA-MRSA CC398 currently causes about 574 
2% of all human MRSA infections in Germany, but up to 10% in regions 575 
characterized by a high density of livestock farming.100 Likewise, a study investigating 576 
629 ESBL-producing E. coli from people in the Netherlands, Germany and UK, which 577 
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were collected during the years 2005-2009 and examined by DNA microarray and 578 
multi-locus sequence typing (MLST), showed that the majority of the human isolates 579 
differed distinctly from isolates of animal origin due to diversity in virulence and 580 
antimicrobial resistance genes.101 It was concluded that attempts to minimize the 581 
human-to-human transfer of ESBL-producing E. coli are essential to limit the 582 
dissemination of these bacteria among humans. ESBL-producing E. coli from 583 
animals may play a role as a reservoir of virulence and antimicrobial resistance 584 
genes rather than directly causing infections in humans.101 585 
 586 
The methodological attempts to prove the transfer of resistant bacteria or resistance 587 
genes strongly depend on the location of the resistance gene. For bacteria such as 588 
MRSA, where the meticillin resistance genes mecA or mecC are located on a 589 
chromosomally integrated SCCmec cassette, molecular strain typing methods can be 590 
applied. These include pattern-based techniques, such as PFGE, or sequence-based 591 
methods such as MLST, single locus sequence typing via spa and dru typing, as well 592 
as multiple loci VNTR analysis (MLVA).102, 103 In addition, the presence of the 593 
relevant resistance genes can be detected by PCR. Whole-genome sequencing with 594 
subsequent SNP analysis can also be used as the ultimate proof.81, 104 The results of 595 
these methods can enable definite proof of clonality and transference of resistance 596 
genes. 597 
 598 
If a resistance gene is located on a MGE (e.g. plasmid-borne ESBL genes in E. coli) 599 
strain typing methods like PFGE, MLST or PCR-directed typing methods can still be 600 
applied. In addition, it is necessary also to characterize the resistance plasmid in 601 
question (e.g. by pMLST, replicon typing, restriction analysis or even whole plasmid 602 
sequencing).105 In the transfer of resistance plasmids, different scenarios are 603 
conceivable. Scenario 1 describes a situation where the transferred strain and its 604 
resistance plasmid multiply stably in the new host. In such a case, the 605 
aforementioned methods enable the verification of the transferred strain and the 606 
resistance plasmid.106 In scenario 2, the transferred strain cannot replicate in the new 607 
host, but transfers its resistance plasmid to bacteria of the new host. In this case, the 608 
transferred strain is not detectable any more, but the resistance plasmid may be 609 
detected in the new host bacteria. Scenario 3 describes a situation in which the 610 
transferred strain cannot replicate in the new host and the transferred plasmid cannot 611 
replicate in the new host bacteria but undergoes recombination with plasmids already 612 
residing in these new host bacteria. In this case, neither the original bacterial strain 613 
nor the original plasmid are detectable and the confirmation of transfer is not 614 
possible. 615 
 616 
Another problem is the confirmation of the direction of transfer. In staphylococci, for 617 
instance, structurally closely related small mobilizable plasmids that carry the 618 
tetracycline resistance gene tet(K), the chloramphenicol resistance gene catpC221 or 619 
the MLSB resistance gene erm(C) are prevalent in various staphylococcal species 620 
from both humans and animals.107-109 Because tetracyclines, chloramphenicol and 621 
macrolides have been used in human and veterinary medicine for more than 60 622 
years, it is impossible to determine in retrospect where and when these resistance 623 
genes first developed and which transfer events across species and host boundaries 624 
have taken place since then. In contrast, the recently identified phenicol and 625 
oxazolidinone resistance gene optrA is likely to have developed in enterococci of 626 
animal origin in China under the selective pressure imposed by the use of florfenicol 627 
in livestock animals.110 Chloramphenicol was banned from use in food producing 628 
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animals in China in 2002, whereas florfenicol was licensed in 1999 for animals only 629 
and has been used widely since then.110 The first optrA-carrying E. faecium isolate of 630 
human origin orginated in 2005. This happened two years before linezolid, the sole 631 
commercially available oxazolidinone in China, was approved for use in human 632 
medicine in 2007. 633 
 634 
The future of antibacterial therapy 635 
 636 
For surface and superficial skin infections, and otitis involving multidrug-resistant 637 
bacteria, topical antimicrobial therapy is likely to remain effective in the future because 638 
very high concentrations of the drug, easily exceeding MICs, can be achieved at the 639 
site of infection.111, 112 However, for deep infections or those requiring systemic 640 
therapy, new classes of antimicrobial agents are unlikely to be approved for veterinary 641 
medicine. All new classes of antimicrobial agents will first be tested for their suitability 642 
as therapeutics in human medicine. Only if a new class of antimicrobial agents is 643 
unsuitable for use in humans based on its pharmacological parameters, toxicity or 644 
adverse effects, may it be considered for veterinary applications. The antimicrobial 645 
agents approved for veterinary use during the last 15 years are all derivatives of 646 
already known substances. Thus, pradofloxacin is a fluoroquinolone with improved 647 
activity against canine and feline bacterial pathogens. Tulathromycin, tildipirosin and 648 
gamithromycin are macrolides for the control of bovine and porcine respiratory tract 649 
infections. Finally, florfenicol is a fluorinated phenicol with activity against 650 
chloramphenicol-resistant bacteria in which resistance is based on a chloramphenicol 651 
acetyltransferase. Florfenicol is an example where the detailed knowledge about the 652 
resistance mechanism has led to the development of a molecule which is resistant to 653 
enzymatic inactivation by acetylation.10 However, soon after the introduction of 654 
florfenicol into clinical veterinary use, genes specifying other phenicol resistance 655 
mechanisms, which also confer resistance to florfenicol, have emerged.10, 17 656 
 657 
It is our responsibility to use the available antimicrobial agents wisely and try to 658 
preserve their activity for as long as possible. This needs to include following 659 
pharmacokinetic and pharmacodynamic data (and creating such data where they are 660 
not yet available) for agents that are not licensed for use in pets. One example is use 661 
of the published recommendations on minocycline.113 Most importantly, prudent use 662 
guidelines must be followed alongside the well-proven (but still too frequently 663 
neglected) concepts of rigorous hygiene measures. Moreover, improved 664 
microbiological diagnostics, which also include harmonized protocols for antimicrobial 665 
susceptibility testing of the various veterinary bacterial pathogens and additional 666 
veterinary-specific clinical breakpoints, especially for bacteria of poultry and fish origin, 667 
are urgently needed. 668 
 669 
In summary, a multifaceted holistic approach which takes into account education as 670 
well as antimicrobial stewardship, is required:114 671 
 672 
Education of the public in addition to prescribers of antimicrobial drugs is needed. 673 
Understanding how antimicrobial agents work and under which conditions 674 
antimicrobial resistance develops and spreads promotes the awareness needed to 675 
implement measures that counteract resistance development. Examples of such 676 
educational measures are the pan-European e-Bug program,115, 116 the “Get smart” 677 
program of US Centers for Disease Control and Prevention,117 and antibiotic 678 
awareness days promoted in Europe and Canada.118, 119 679 
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 680 
The search for new antimicrobial agents – natural and synthetic – should be stimulated 681 
by making the development of new agents more attractive to the pharmaceutical 682 
industry (e.g. by expanding the time of patent protection or lowering the administrative 683 
hurdles in the approval process). Public–private partnerships, which take the 684 
development of new antimicrobial agents forward, should be encouraged. As 685 
mentioned for florfenicol, more efforts also should be made to develop chemical 686 
modifications which provide antimicrobial derivatives that evade known resistance 687 
mechanisms. 688 
 689 
Revival of “old” antimicrobial agents, including those discarded, not fully developed or 690 
even rejected, should be re-investigated. Combinations of antimicrobial agents with an 691 
inhibitor (e.g. an efflux inhibitor) should be explored for their ability to restore the activity 692 
of old antimicrobial agents.120 693 
 694 
Control of the use of antimicrobial agents: As the selective pressure imposed by the 695 
use of antimicrobial agents is a major driving force in the development of antimicrobial 696 
resistance, the nontherapeutic use of antimicrobial agents, for example, as growth 697 
promoters, must be discontinued worldwide. Antimicrobial agents in humans and 698 
animals should be made available by prescription only. Over-the-counter sales of 699 
antimicrobial agents should be forbidden worldwide. Monitoring of the consumption of 700 
antimicrobial agents in both human and veterinary medicine, including antimicrobial 701 
use in small animal practice, should be implemented. 702 
 703 
Alternatives to antimicrobial agents: Novel nonantibiotic approaches for prevention of 704 
and protection against infectious diseases should be explored.121 These include the 705 
development of vaccines (especially for animal diseases), phage therapy122, 123 and 706 
phage lysin therapy,124-126 adjuvants, antivirulence therapies (including synthetic 707 
polypeptides that neutralize bacterial pathogenicity factors),127 pre- and probiotics, 708 
immunostimulants, antimicrobial peptides (such as cathelicidins, defensins and 709 
dermicins),128, 129 anti-biofilm therapies130-132 and reprogrammed nucleases that target 710 
antimicrobial resistance genes.133 711 
  712 
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Figure 1. Schematic presentation of the dissemination of resistant bacteria and 1102 
resistance genes among different hosts with particular reference to the exchange  1103 
between humans and animals. The thickness of the different arrows shall indicate the 1104 
likelihood of the various transfer ways. 1105 
 1106 
 1107 
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Table 1. CLSI-approved clinical breakpoints available for skin and soft tissue 1113 
infections as well as wounds in animals8 1114 
 1115 
Animal 
species 
Target bacteria Antimicrobial 
agent 
Clinical breakpoints (mg/L)* 
   S I R 
Dog E. coli Ampicillin ≤ 0.25 0.5 ≥ 1 
 S. pseudintermedius Ampicillin ≤ 0.25 ─ ≥ 0.5 
 Streptococcus spp.,      
S. canis (group G,         
β-hemolytic group) 
Ampicillin ≤ 0.25 ─ ─ 
 E. coli,    
Staphylococcus spp., 
Streptococcus spp. 
Amoxicillin-
clavulanate 
≤ 0.25/0.12 0.5/0.25 ≥ 1/0.5 
 E. coli, S. aureus,         
S. pseudintermedius, 
Streptococcus spp.     
(β-hemolytic group) 
Cephalothin ≤ 2 4 ≥ 8 
 E. coli, P. multocida,     
S. aureus,                     
S. pseudintermedius, 
Streptococcus spp.     
(β-hemolytic group) 
Cefazolin ≤ 2 4 ≥ 8 
 E. coli, P. mirabilis,       
P. multocida, S. 
aureus, S. 
pseudintermedius,     
S. canis (group G, β-
hemolytic group) 
Cefpodoxime ≤ 2 4 ≥ 8 
 Enterobacteriaceae, 
Staphylococcus spp., 
Streptococcus spp. 
Difloxacin ≤ 0.5 1-2 ≥ 4 
 Enterobacteriaceae, 
Staphylococcus spp., 
Streptococcus spp. 
Enrofloxacin ≤ 0.5 1-2 ≥ 4 
 Enterobacteriaceae, 
Staphylococcus spp., 
Streptococcus spp. 
Marbofloxacin ≤ 1 2 ≥ 4 
 Enterobacteriaceae, 
Staphylococcus spp., 
Streptococcus spp. 
Orbifloxacin ≤ 1 2-4 ≥ 8 
 E. coli,                           
S. pseudintermedius 
Pradofloxacin ≤ 0.25 0.5-1 ≥ 2 
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 Staphylococcus spp., 
Streptococcus spp.      
(β-hemolytic group) 
Clindamycin ≤ 0.5 1-2 ≥ 4 
 S. pseudintermedius Doxycycline ≤ 0.12 0.25 ≥ 0.5 
 Staphylococcus spp. Tetracycline ≤ 0.25 0.5 ≥ 1 
      
Cats E. coli,     
Staphylococcus spp., 
Streptococcus spp. 
Amoxicillin-
clavulanate 
≤ 0.25/0.12 0.5/0.25 ≥ 1/0.5 
 Enterobacteriaceae,     
P. aeruginosa, 
Staphylococcus spp., 
Streptococcus spp. 
Enrofloxacin ≤ 0.5 1-2 ≥ 4 
 Enterobacteriaceae, 
Staphylococcus spp., 
Streptococcus spp. 
Marbofloxacin ≤ 1 2 ≥ 4 
 Enterobacteriaceae, 
Staphylococcus spp., 
Streptococcus spp. 
Orbifloxacin ≤ 1 2-4 ≥ 8 
 E. coli, S. aureus,         
S. pseudintermedius,   
S. felis 
Pradofloxacin ≤ 0.25 0.5-1 ≥ 2 
 P. multocida, S. canis Pradofloxacin ≤ 0.25 ─ ─ 
 1116 
* S (susceptible), I (intermediate), R (resistant) 1117 
 1118 
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Table 2. Examples of resistance to antimicrobials by enzymatic inactivation (modified from ref. 1) 
 
Resistance 
mechanism 
Resistance 
gene(s) 
Gene product Resistance 
phenotype 
Bacteria involved Location of the 
resistance gene 
chemical 
modification 
aac, aad (ant), aph acetyl-, adenyl-, 
phosphotransferases 
aminoglycosides various Gram+, 
Gram–, aerobic 
bacteria 
T, GC, P, C 
 aad (ant) adenyltransferases aminocyclitols various Gram+, 
Gram–, aerobic 
bacteria 
T, GC, P, C 
 catA, catB acetyltransferases chloramphenicol various Gram+, 
Gram–, aerobic, 
anaerobic bacteria 
P, T, GC, C 
 vat(A-E) acetyltransferases streptogramin A  Staphylococcus, 
Enterococcus 
P, C 
 mph(A-E) phosphotransferases macrolides Escherichia, Shigella, 
Staphylococcus 
P, T, C 
 lnu(A), lnu(B) nucleotidyltransferases lincosamides Staphylococcus P 
 tet(X), tet(37) oxidoreductases tetracyclines Bacteroides T, P 
hydrolytic cleavage blaZ, blaTEM, 
blaSHV, blaCTX-M, 
etc. 
-lactamases -lactam antibiotics various Gram+, 
Gram–, aerobic, 
anaerobic bacteria 
P, T, GC, C 
 ere(A), ere(B) esterase macrolides E. coli, 
Staphylococcus 
P, GC 
 28 
 vgb(A), vgb(B) lactone hydrolases streptogramin B  Staphylococcus P 
a P = plasmid; T = transposon; GC = gene cassette; C = chromosomal DNA  
 29 
Table 3. Examples of resistance to antimicrobials by decreased intracellular drug accumulation (modified from ref. 1) 
 
Resistance 
mechanism 
Resistance 
gene(s) 
Gene product Resistance 
phenotype 
Bacteria involved Location of the 
resistance gene 
efflux via multidrug 
transporters 
mexA-mexB-
oprM, acrA-acrB-
tolC 
multidrug efflux in 
combination with 
specific OMP’s 
chloramphenicol, β-
lactams, macrolides, 
fluoroquinolones, 
tetracyclines, etc. 
Pseudomonas,  
E. coli, Salmonella 
C 
 emrE 4-TMS multidrug efflux 
protein 
tetracyclines, nucleic 
acid binding 
compounds 
E. coli C 
 blt, norA 12-TMS multidrug 
efflux protein of the 
major facilitator 
superfamily 
chloramphenicol, 
fluoroquinolones, 
nucleic acid binding 
compounds 
Bacillus, 
Staphylococcus 
C 
efflux via specific 
exporters 
tet(A-E, G, H, I, J, 
K, L, Z), tetA(P), 
tet(30) 
12-, 14-TMS efflux 
system of the major 
facilitator superfamily 
tetracyclines various Gram+ and 
Gram– bacteria 
P, T, C 
 floR 12 TMS efflux system 
of the major facilitator 
superfamily 
phenicols various Gram– 
bacteria 
T, P, C 
 cmlA, cmlB 12 TMS efflux system 
of the major facilitator 
superfamily 
chloramphenicol various Gram– 
bacteria 
T, P, GC, C 
 30 
 fexA 14 TMS efflux system 
of the major facilitator 
superfamily 
phenicols Staphylococcus T, P, C 
 mef(A) efflux system of the 
major facilitator 
superfamily 
14-, 15-membered 
macrolides 
Streptococcus, other 
Gram+ bacteria  
T, P, C 
 msr(A) efflux system of the 
ABC transporter family 
macrolides and 
streptogramin B 
Staphylococcus P 
 vga(A), vga(C), 
vga(E), lsa(E), 
sal(A) 
efflux system of the 
ABC transporter family 
streptogramin A, lin Staphylococcus, 
Enterococcus 
P 
 optrA efflux system of the 
ABC transporter family 
phenicols, linezolid, 
tedizolid  
Enterococcus, 
Staphylococcus 
P, C 
a P = plasmid; T = transposon; GC = gene cassette; C = chromosomal DNA 
b TMS = transmembrane segments 
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Table 4. Examples of resistance to antimicrobials by target site alteration (modified from ref. 1) 
 
Resistance 
mechanism 
Resistance 
gene(s) 
Gene product Resistance 
phenotype 
Bacteria involved Location of the 
resistance gene 
methylation of the 
target site 
erm(A-46) rRNA methylase macrolides, 
lincosamides, 
streptogramin B 
various Gram+  and 
Gram–  bacteria 
P, T, C 
methylation of the 
target site 
cfr, cfrB rRNA methylase phenicols, 
lincosamides, 
linezolid, 
pleuromutilins, 
streptogramin A 
various Gram+  and  
Gram–  bacteria 
P, C 
protection of the 
target site 
tet(M, O, P, Q, S, 
T) 
ribosome protective 
proteins 
tetracyclines  various Gram+  and  
Gram–  bacteria 
T, P, C 
 fusB ribosome protective 
protein 
fusidic acid Staphylococcus P 
replacement of a 
sensitive target by an 
alternative drug-
resistant target 
mecA, mecC penicillin-binding proteins 
with altered substrate 
specificity 
penicillins, 
cephalosporins, 
carbapenems, 
monobactams 
Staphylococcus C 
 sul1, sul2, sul3 sulfonamide-insensitive 
dihydropteroate 
synthase 
sulfonamides various Gram–  
bacteria 
P, I 
dfrA, dfrB trimethoprim-insensitive 
dihydrofolate reductase 
trimethoprim various Gram+  and  
Gram–  bacteria 
P, GC, T, C 
 32 
 mupA, ileS2 mupirocin-insensitive 
isoleucyl-tRNA synthase 
mupirocin Staphylococcus P 
 vanA-E alternative peptide-
glycan precursors  
glycopeptides Enterococcus, 
Staphylococcus 
T, P, C 
mutational 
modification of the 
target site 
 mutations in the genes 
for topoisomerase II and 
IV 
fluoroquinolones various Gram+  and  
Gram– bacteria 
C 
  mutation in the gene 
coding for ribosomal 
protein S12 
streptomycin several Gram+  and  
Gram–  bacteria 
C 
  mutation in the gene for 
the ribosomal protein L3 
tiamulin E. coli C 
  mutation in the 16S 
rRNA 
tetracyclines Propionibacterium C 
  mutations in the 23S 
rRNA 
oxazolidinones Staphylococcus C 
  mutation in the fusA 
gene 
fusidic acid Staphylococcus C 
mutational 
modification of 
regulatory elements 
 mutations in the marRAB 
soxR or acrR genes 
fluoroquinolones E. coli C 
a P = plasmid; T = transposon; GC = gene cassette; C = chromosomal DNA, I = integron 
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Zusammenfassung 
 
Hintergrund – Antimikrobielle Resistenz hat sich zu einer zunehmenden 
Herausforderung in der Veterinärmedizin entwickelt, insbesondere im 
Zusammenhang mit bakteriellen Infektionserregern, die bei Menschen und Tieren 
eine Rolle spielen.  
 
Ziele – Dieser Artikel vermittelt eine aktuelle Übersicht über erworbene 
Resistenzmechanismen von Bakterien, die an Hautinfektionen von Tieren beteiligt 
sind. Zusätzlich enthält er Beispiele für den Transfer resistenter Infektionserreger 
zwischen verschiedenen Wirten und für den Transfer von Resistenzgenen zwischen 
Bakterien von Tieren und Menschen. 
 
Ergebnisse – Erworbene Resistenz basiert auf resistenzvermittelnden Mutationen 
oder mobilen Resistenzgenen. Während Mutationen vertikal weitergegeben werden, 
erfolgt der Transfer mobiler Resistenzgene auch horizontal (mittels Transformation, 
Transduktion oder Konjugation/Mobilisierung) und trägt dadurch zur Verbreitung 
antimikrobieller Resistenzen bei. Bisher wurden mobile Resistenzgene, die einen der 
drei Resistenzmechanismen – enzymatische Inaktivierung, reduzierte intrazelluläre 
Akkumulation oder Modifizierung der zellulären Angriffsstellen – vermitteln bei einer 
Vielzahl von Bakterien nachgewiesen. Solche Resistenzgene liegen als Bestandteil 
von Plasmiden, Transposons, Genkassetten, integrativen und konjugativen 
Elementen oder anderer mobiler Elemente vor. Bakterien, einschließlich zoonotischer 
Infektionserreger, können zwischen Tieren und Menschen hauptsächlich durch 
direkten Kontakt, aber auch über Staub und Aerosole sowie Lebensmittel 
ausgetauscht werden. Der Nachweis der Transferrichtung von resistenten Bakterien 
kann sich schwierig gestalten und hängt von der Lokalisation der Resistenzgene 
oder Mutationen in der chromosomalen DNA oder auf mobilen Elementen ab. 
 
Schlussfolgerungen – Die große Vielfalt an Resistenz- und Transfermechanismen 
wird auch in Zukunft den Erfolg bakterieller Infektionserreger sichern. Unsere 
Strategien der Resistenzentwicklung entgegen zu wirken und die Wirksamkeit  
antimikrobieller Wirkstoffe zu erhalten muss ähnlich vielfältig und erfindungsreich 
sein. 
 
 
 
 
 
